Michael Makris/LinkedIn
Apr 17, 2026, 14:43
Michael Makris: Are Rebalancing Agents in Hemophilia Associated with Thrombosis?
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at University of Sheffield, shared a post on LinkedIn about his recent article, published in the Journal of Thrombosis and Haemostasis։
”The PDF of my Forum article on the potential thrombogenicity of the ‘rebalancing’ agents is now available on the Journal of Thrombosis and Haemostasis website.”
Title: How real is the thrombotic risk with the rebalancing agents used to treat hemophilia?
Author: Michael Makris
Other posts featuring Michael Makris on Hemostasis Today.
-
Apr 17, 2026, 14:34Eric Topol: The Role of Sex Hormones in Venous Thromboembolism and Cardiovascular Disease Risk
-
Apr 17, 2026, 14:30Paschalis Evangelidis: A New Way to Treat iTTP by Targeting the Autoimmune Process
-
Apr 17, 2026, 14:27Happy World Hemophilia Day – WFH
-
Apr 17, 2026, 13:59Donna Morelli: Personalized Cardiovascular Risk Assessment Through AI-Based Multiomics Modeling
-
Apr 17, 2026, 13:27Abdalraheim Mustafa: Comparative Analysis of Thrombophilia and Thrombocytosis in Clinical Practice
-
Apr 17, 2026, 13:25Emphasizing The Importance Of Early Diagnosis For Improving Hemophilia Care In Armenia – Yeolyan Hematology and Oncology Center
-
Apr 17, 2026, 13:05Flora Peyvandi: Key Guidance from ISTH on Pediatric Antithrombotic Therapies
-
Apr 17, 2026, 12:44Marc Carrier: A Practical Approach to Recurrent Thrombosis in Cancer Patients
-
Apr 17, 2026, 12:15Zain Khalpey: The Hidden Impact of Sex Hormones on Thrombosis and Heart Health